0

Close
 
Upcoming Allied Market Research
2023
Butylscopolamine Market

Butylscopolamine Market

by Therapy Type (Analgesia, Smooth Muscle Relaxation, Radiological Procedure), by Condition (Gastrointestinal Spastic, Acute Biliary Spasm, Hypermotility Disorder, Menstrual Distress, Primary Dysmenorrhea, Muscle Spasm, Acute Genitourinary Spasm) and by Application (Injection, Oral): Global Opportunity Analysis and Industry Forecast, 2023-2032

LS : Pharmaceuticals
Report Code: A14426
Nov 2023 | Pages: NA
Tables: NA
Charts: NA

  • Formats*:

  • pdf

    Single User License, Five User
    License & Enterprise User License

  • xls

    Data Pack Excel License

  • ppt

    It comes with the additional cost
    of $2500.00 contact sales.
 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Butylscopolamine Market

Request Now !

Butylscopolamine is an anticholinergic and antimuscarinic medication, mostly in tablet form, which is used to treat disorders related to irritable bowel syndrome such as stomach cramps, abdominal pians, renal colic, or spasmodic discomforts, including esophageal spasm and bladder spasm. Along with the mentioned pains and discomforts, this drug helps to improve respiratory secretions. This is not exactly a pain medication, as it does not directly act on reducing the pain but helps to prevent the painful cramps. It acts by relaxing the muscle of the bowel or other target area.

Impact of COVID-19 Pandemic on Butylscopolamine Market (Pre and Post Analysis)

Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are facing shortage of these drugs. Thus, the pharmaceutical and biotechnology industries are expected to witness a significant growth in the future, owing to the demand for vaccine and treatment drugs for COVID-19. This, in turn, is expected to have a significant impact on the butylscopolamine market.

Top Impacting Factors

  • Rise in unhealthy lifestyle of the people is the reason for increasing cases of bowel disorder, which leads to the growth of butylscopolamine market.
  • Increase in geriatric population results in more incidences of muscle spasm, which has further boosted the growth of the market.
  • However, lack of knowledge about the medication in many countries hampers the growth of the butylscopolamine market.

Market Trends
New Product Launches to Flourish the Market

In 2019, European Bioinformatics Institute, an intergovernmental organization, launched butylscopolamine bromide (CHEBI:32123) to provide relief to painful stomach cramps. 

Key Benefits of the Report

  • This study presents the analytical depiction of the butylscopolamine industry along with the current trends and future estimations to determine the imminent investment pockets.
  • The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the butylscopolamine market share.
  • The current market is quantitatively analyzed to highlight the market growth scenario.
  • Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market. 
  • The report provides a detailed market analysis depending on competitive intensity and how the competition will take shape in coming years

Questions answered in the butylscopolamine report

  • Who are the leading players active in the butylscopolamine market?
  • What are the current trends that will influence the market in the next few years?
  • What are the driving factors, restraints, and opportunities of the market?
  • What future projections would help in taking further strategic steps?
  • What is "butylscopolamine"?

 Butylscopolamine Market Report Highlights

Aspects Details
By Therapy Type
  • Analgesia
  • Smooth Muscle Relaxation
  • Radiological Procedure
By Condition
  • Gastrointestinal Spastic
  • Acute Biliary Spasm
  • Hypermotility Disorder
  • Menstrual Distress
  • Primary Dysmenorrhea
  • Muscle Spasm
  • Acute Genitourinary Spasm
By Application
  • Injection
  • Oral
By Region
  • North America  (U.S, Canada, Mexico)
  • Europe  (Germany, France, UK, Italy, Spain, Rest of Europe)
  • Asia-Pacific  (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific)
  • LAMEA  (Brazil, Saudi Arabia, South Africa, Rest of LAMEA)
Key Market Players Syntree, Alkaloida Corp, Shandong Yijian Pharmaceutical Sigma-Aldrich, Linnea, AvaChem Scientific, Guangdong Zhongsheng Pharmaceutical, XI AN TIANXINGJIAN PHARMCHEM, Parchem, Wolves RandD chemical, Combi-Blocks, OXCHEM CORPORATION, Sandoz (Novartis), Wanbangde Pharmaceutical Group, Jiangsu Ange Pharmaceutical, Boehringer Ingelheim, Chengdu First Pharmaceutical
 

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

    • 3.6. COVID-19 Impact Analysis

  • CHAPTER 4: BUTYLSCOPOLAMINE MARKET, BY THERAPY TYPE

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Therapy Type

    • 4.2. Analgesia

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. Smooth Muscle Relaxation

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

    • 4.4. Radiological Procedure

      • 4.4.1. Key Market Trends, Growth Factors and Opportunities

      • 4.4.2. Market Size and Forecast, By Region

      • 4.4.3. Market Share Analysis, By Country

  • CHAPTER 5: BUTYLSCOPOLAMINE MARKET, BY CONDITION

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By Condition

    • 5.2. Gastrointestinal Spastic

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. Acute Biliary Spasm

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

    • 5.4. Hypermotility Disorder

      • 5.4.1. Key Market Trends, Growth Factors and Opportunities

      • 5.4.2. Market Size and Forecast, By Region

      • 5.4.3. Market Share Analysis, By Country

    • 5.5. Menstrual Distress

      • 5.5.1. Key Market Trends, Growth Factors and Opportunities

      • 5.5.2. Market Size and Forecast, By Region

      • 5.5.3. Market Share Analysis, By Country

    • 5.6. Primary Dysmenorrhea

      • 5.6.1. Key Market Trends, Growth Factors and Opportunities

      • 5.6.2. Market Size and Forecast, By Region

      • 5.6.3. Market Share Analysis, By Country

    • 5.7. Muscle Spasm

      • 5.7.1. Key Market Trends, Growth Factors and Opportunities

      • 5.7.2. Market Size and Forecast, By Region

      • 5.7.3. Market Share Analysis, By Country

    • 5.8. Acute Genitourinary Spasm

      • 5.8.1. Key Market Trends, Growth Factors and Opportunities

      • 5.8.2. Market Size and Forecast, By Region

      • 5.8.3. Market Share Analysis, By Country

  • CHAPTER 6: BUTYLSCOPOLAMINE MARKET, BY APPLICATION

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By Application

    • 6.2. Injection

      • 6.2.1. Key Market Trends, Growth Factors and Opportunities

      • 6.2.2. Market Size and Forecast, By Region

      • 6.2.3. Market Share Analysis, By Country

    • 6.3. Oral

      • 6.3.1. Key Market Trends, Growth Factors and Opportunities

      • 6.3.2. Market Size and Forecast, By Region

      • 6.3.3. Market Share Analysis, By Country

  • CHAPTER 7: BUTYLSCOPOLAMINE MARKET, BY REGION

    • 7.1. Market Overview

      • 7.1.1 Market Size and Forecast, By Region

    • 7.2. North America

      • 7.2.1. Key Market Trends and Opportunities

      • 7.2.2. Market Size and Forecast, By Therapy Type

      • 7.2.3. Market Size and Forecast, By Condition

      • 7.2.4. Market Size and Forecast, By Application

      • 7.2.5. Market Size and Forecast, By Country

      • 7.2.6. U.S. Butylscopolamine Market

        • 7.2.6.1. Market Size and Forecast, By Therapy Type
        • 7.2.6.2. Market Size and Forecast, By Condition
        • 7.2.6.3. Market Size and Forecast, By Application

      • 7.2.7. Canada Butylscopolamine Market

        • 7.2.7.1. Market Size and Forecast, By Therapy Type
        • 7.2.7.2. Market Size and Forecast, By Condition
        • 7.2.7.3. Market Size and Forecast, By Application

      • 7.2.8. Mexico Butylscopolamine Market

        • 7.2.8.1. Market Size and Forecast, By Therapy Type
        • 7.2.8.2. Market Size and Forecast, By Condition
        • 7.2.8.3. Market Size and Forecast, By Application

    • 7.3. Europe

      • 7.3.1. Key Market Trends and Opportunities

      • 7.3.2. Market Size and Forecast, By Therapy Type

      • 7.3.3. Market Size and Forecast, By Condition

      • 7.3.4. Market Size and Forecast, By Application

      • 7.3.5. Market Size and Forecast, By Country

      • 7.3.6. France Butylscopolamine Market

        • 7.3.6.1. Market Size and Forecast, By Therapy Type
        • 7.3.6.2. Market Size and Forecast, By Condition
        • 7.3.6.3. Market Size and Forecast, By Application

      • 7.3.7. Germany Butylscopolamine Market

        • 7.3.7.1. Market Size and Forecast, By Therapy Type
        • 7.3.7.2. Market Size and Forecast, By Condition
        • 7.3.7.3. Market Size and Forecast, By Application

      • 7.3.8. Italy Butylscopolamine Market

        • 7.3.8.1. Market Size and Forecast, By Therapy Type
        • 7.3.8.2. Market Size and Forecast, By Condition
        • 7.3.8.3. Market Size and Forecast, By Application

      • 7.3.9. Spain Butylscopolamine Market

        • 7.3.9.1. Market Size and Forecast, By Therapy Type
        • 7.3.9.2. Market Size and Forecast, By Condition
        • 7.3.9.3. Market Size and Forecast, By Application

      • 7.3.10. UK Butylscopolamine Market

        • 7.3.10.1. Market Size and Forecast, By Therapy Type
        • 7.3.10.2. Market Size and Forecast, By Condition
        • 7.3.10.3. Market Size and Forecast, By Application

      • 7.3.11. Russia Butylscopolamine Market

        • 7.3.11.1. Market Size and Forecast, By Therapy Type
        • 7.3.11.2. Market Size and Forecast, By Condition
        • 7.3.11.3. Market Size and Forecast, By Application

      • 7.3.12. Rest Of Europe Butylscopolamine Market

        • 7.3.12.1. Market Size and Forecast, By Therapy Type
        • 7.3.12.2. Market Size and Forecast, By Condition
        • 7.3.12.3. Market Size and Forecast, By Application

    • 7.4. Asia-Pacific

      • 7.4.1. Key Market Trends and Opportunities

      • 7.4.2. Market Size and Forecast, By Therapy Type

      • 7.4.3. Market Size and Forecast, By Condition

      • 7.4.4. Market Size and Forecast, By Application

      • 7.4.5. Market Size and Forecast, By Country

      • 7.4.6. China Butylscopolamine Market

        • 7.4.6.1. Market Size and Forecast, By Therapy Type
        • 7.4.6.2. Market Size and Forecast, By Condition
        • 7.4.6.3. Market Size and Forecast, By Application

      • 7.4.7. Japan Butylscopolamine Market

        • 7.4.7.1. Market Size and Forecast, By Therapy Type
        • 7.4.7.2. Market Size and Forecast, By Condition
        • 7.4.7.3. Market Size and Forecast, By Application

      • 7.4.8. India Butylscopolamine Market

        • 7.4.8.1. Market Size and Forecast, By Therapy Type
        • 7.4.8.2. Market Size and Forecast, By Condition
        • 7.4.8.3. Market Size and Forecast, By Application

      • 7.4.9. South Korea Butylscopolamine Market

        • 7.4.9.1. Market Size and Forecast, By Therapy Type
        • 7.4.9.2. Market Size and Forecast, By Condition
        • 7.4.9.3. Market Size and Forecast, By Application

      • 7.4.10. Australia Butylscopolamine Market

        • 7.4.10.1. Market Size and Forecast, By Therapy Type
        • 7.4.10.2. Market Size and Forecast, By Condition
        • 7.4.10.3. Market Size and Forecast, By Application

      • 7.4.11. Thailand Butylscopolamine Market

        • 7.4.11.1. Market Size and Forecast, By Therapy Type
        • 7.4.11.2. Market Size and Forecast, By Condition
        • 7.4.11.3. Market Size and Forecast, By Application

      • 7.4.12. Malaysia Butylscopolamine Market

        • 7.4.12.1. Market Size and Forecast, By Therapy Type
        • 7.4.12.2. Market Size and Forecast, By Condition
        • 7.4.12.3. Market Size and Forecast, By Application

      • 7.4.13. Indonesia Butylscopolamine Market

        • 7.4.13.1. Market Size and Forecast, By Therapy Type
        • 7.4.13.2. Market Size and Forecast, By Condition
        • 7.4.13.3. Market Size and Forecast, By Application

      • 7.4.14. Rest of Asia Pacific Butylscopolamine Market

        • 7.4.14.1. Market Size and Forecast, By Therapy Type
        • 7.4.14.2. Market Size and Forecast, By Condition
        • 7.4.14.3. Market Size and Forecast, By Application

    • 7.5. LAMEA

      • 7.5.1. Key Market Trends and Opportunities

      • 7.5.2. Market Size and Forecast, By Therapy Type

      • 7.5.3. Market Size and Forecast, By Condition

      • 7.5.4. Market Size and Forecast, By Application

      • 7.5.5. Market Size and Forecast, By Country

      • 7.5.6. Brazil Butylscopolamine Market

        • 7.5.6.1. Market Size and Forecast, By Therapy Type
        • 7.5.6.2. Market Size and Forecast, By Condition
        • 7.5.6.3. Market Size and Forecast, By Application

      • 7.5.7. South Africa Butylscopolamine Market

        • 7.5.7.1. Market Size and Forecast, By Therapy Type
        • 7.5.7.2. Market Size and Forecast, By Condition
        • 7.5.7.3. Market Size and Forecast, By Application

      • 7.5.8. Saudi Arabia Butylscopolamine Market

        • 7.5.8.1. Market Size and Forecast, By Therapy Type
        • 7.5.8.2. Market Size and Forecast, By Condition
        • 7.5.8.3. Market Size and Forecast, By Application

      • 7.5.9. UAE Butylscopolamine Market

        • 7.5.9.1. Market Size and Forecast, By Therapy Type
        • 7.5.9.2. Market Size and Forecast, By Condition
        • 7.5.9.3. Market Size and Forecast, By Application

      • 7.5.10. Argentina Butylscopolamine Market

        • 7.5.10.1. Market Size and Forecast, By Therapy Type
        • 7.5.10.2. Market Size and Forecast, By Condition
        • 7.5.10.3. Market Size and Forecast, By Application

      • 7.5.11. Rest of LAMEA Butylscopolamine Market

        • 7.5.11.1. Market Size and Forecast, By Therapy Type
        • 7.5.11.2. Market Size and Forecast, By Condition
        • 7.5.11.3. Market Size and Forecast, By Application

  • CHAPTER 8: COMPETITIVE LANDSCAPE

    • 8.1. Introduction

    • 8.2. Top Winning Strategies

    • 8.3. Product Mapping Of Top 10 Player

    • 8.4. Competitive Dashboard

    • 8.5. Competitive Heatmap

    • 8.6. Top Player Positioning,2022

  • CHAPTER 9: COMPANY PROFILES

    • 9.1. Guangdong Zhongsheng Pharmaceutical

      • 9.1.1. Company Overview

      • 9.1.2. Key Executives

      • 9.1.3. Company Snapshot

      • 9.1.4. Operating Business Segments

      • 9.1.5. Product Portfolio

      • 9.1.6. Business Performance

      • 9.1.7. Key Strategic Moves and Developments

    • 9.2. Wanbangde Pharmaceutical Group

      • 9.2.1. Company Overview

      • 9.2.2. Key Executives

      • 9.2.3. Company Snapshot

      • 9.2.4. Operating Business Segments

      • 9.2.5. Product Portfolio

      • 9.2.6. Business Performance

      • 9.2.7. Key Strategic Moves and Developments

    • 9.3. Shandong Yijian Pharmaceutical Sigma-Aldrich

      • 9.3.1. Company Overview

      • 9.3.2. Key Executives

      • 9.3.3. Company Snapshot

      • 9.3.4. Operating Business Segments

      • 9.3.5. Product Portfolio

      • 9.3.6. Business Performance

      • 9.3.7. Key Strategic Moves and Developments

    • 9.4. Alkaloida Corp

      • 9.4.1. Company Overview

      • 9.4.2. Key Executives

      • 9.4.3. Company Snapshot

      • 9.4.4. Operating Business Segments

      • 9.4.5. Product Portfolio

      • 9.4.6. Business Performance

      • 9.4.7. Key Strategic Moves and Developments

    • 9.5. Syntree

      • 9.5.1. Company Overview

      • 9.5.2. Key Executives

      • 9.5.3. Company Snapshot

      • 9.5.4. Operating Business Segments

      • 9.5.5. Product Portfolio

      • 9.5.6. Business Performance

      • 9.5.7. Key Strategic Moves and Developments

    • 9.6. Linnea

      • 9.6.1. Company Overview

      • 9.6.2. Key Executives

      • 9.6.3. Company Snapshot

      • 9.6.4. Operating Business Segments

      • 9.6.5. Product Portfolio

      • 9.6.6. Business Performance

      • 9.6.7. Key Strategic Moves and Developments

    • 9.7. AvaChem Scientific

      • 9.7.1. Company Overview

      • 9.7.2. Key Executives

      • 9.7.3. Company Snapshot

      • 9.7.4. Operating Business Segments

      • 9.7.5. Product Portfolio

      • 9.7.6. Business Performance

      • 9.7.7. Key Strategic Moves and Developments

    • 9.8. Wolves RandD Chemical

      • 9.8.1. Company Overview

      • 9.8.2. Key Executives

      • 9.8.3. Company Snapshot

      • 9.8.4. Operating Business Segments

      • 9.8.5. Product Portfolio

      • 9.8.6. Business Performance

      • 9.8.7. Key Strategic Moves and Developments

    • 9.9. Boehringer Ingelheim

      • 9.9.1. Company Overview

      • 9.9.2. Key Executives

      • 9.9.3. Company Snapshot

      • 9.9.4. Operating Business Segments

      • 9.9.5. Product Portfolio

      • 9.9.6. Business Performance

      • 9.9.7. Key Strategic Moves and Developments

    • 9.10. Sandoz (Novartis)

      • 9.10.1. Company Overview

      • 9.10.2. Key Executives

      • 9.10.3. Company Snapshot

      • 9.10.4. Operating Business Segments

      • 9.10.5. Product Portfolio

      • 9.10.6. Business Performance

      • 9.10.7. Key Strategic Moves and Developments

    • 9.11. Jiangsu Ange Pharmaceutical

      • 9.11.1. Company Overview

      • 9.11.2. Key Executives

      • 9.11.3. Company Snapshot

      • 9.11.4. Operating Business Segments

      • 9.11.5. Product Portfolio

      • 9.11.6. Business Performance

      • 9.11.7. Key Strategic Moves and Developments

    • 9.12. Chengdu First Pharmaceutical

      • 9.12.1. Company Overview

      • 9.12.2. Key Executives

      • 9.12.3. Company Snapshot

      • 9.12.4. Operating Business Segments

      • 9.12.5. Product Portfolio

      • 9.12.6. Business Performance

      • 9.12.7. Key Strategic Moves and Developments

    • 9.13. Combi-Blocks

      • 9.13.1. Company Overview

      • 9.13.2. Key Executives

      • 9.13.3. Company Snapshot

      • 9.13.4. Operating Business Segments

      • 9.13.5. Product Portfolio

      • 9.13.6. Business Performance

      • 9.13.7. Key Strategic Moves and Developments

    • 9.14. OXCHEM CORPORATION

      • 9.14.1. Company Overview

      • 9.14.2. Key Executives

      • 9.14.3. Company Snapshot

      • 9.14.4. Operating Business Segments

      • 9.14.5. Product Portfolio

      • 9.14.6. Business Performance

      • 9.14.7. Key Strategic Moves and Developments

    • 9.15. Parchem

      • 9.15.1. Company Overview

      • 9.15.2. Key Executives

      • 9.15.3. Company Snapshot

      • 9.15.4. Operating Business Segments

      • 9.15.5. Product Portfolio

      • 9.15.6. Business Performance

      • 9.15.7. Key Strategic Moves and Developments

    • 9.16. XI AN TIANXINGJIAN PHARMCHEM

      • 9.16.1. Company Overview

      • 9.16.2. Key Executives

      • 9.16.3. Company Snapshot

      • 9.16.4. Operating Business Segments

      • 9.16.5. Product Portfolio

      • 9.16.6. Business Performance

      • 9.16.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL BUTYLSCOPOLAMINE MARKET, BY THERAPY TYPE, 2022-2032 ($MILLION)
  • TABLE 2. GLOBAL BUTYLSCOPOLAMINE MARKET FOR ANALGESIA, BY REGION, 2022-2032 ($MILLION)
  • TABLE 3. GLOBAL BUTYLSCOPOLAMINE MARKET FOR SMOOTH MUSCLE RELAXATION, BY REGION, 2022-2032 ($MILLION)
  • TABLE 4. GLOBAL BUTYLSCOPOLAMINE MARKET FOR RADIOLOGICAL PROCEDURE, BY REGION, 2022-2032 ($MILLION)
  • TABLE 5. GLOBAL BUTYLSCOPOLAMINE MARKET, BY CONDITION, 2022-2032 ($MILLION)
  • TABLE 6. GLOBAL BUTYLSCOPOLAMINE MARKET FOR GASTROINTESTINAL SPASTIC, BY REGION, 2022-2032 ($MILLION)
  • TABLE 7. GLOBAL BUTYLSCOPOLAMINE MARKET FOR ACUTE BILIARY SPASM, BY REGION, 2022-2032 ($MILLION)
  • TABLE 8. GLOBAL BUTYLSCOPOLAMINE MARKET FOR HYPERMOTILITY DISORDER, BY REGION, 2022-2032 ($MILLION)
  • TABLE 9. GLOBAL BUTYLSCOPOLAMINE MARKET FOR MENSTRUAL DISTRESS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 10. GLOBAL BUTYLSCOPOLAMINE MARKET FOR PRIMARY DYSMENORRHEA, BY REGION, 2022-2032 ($MILLION)
  • TABLE 11. GLOBAL BUTYLSCOPOLAMINE MARKET FOR MUSCLE SPASM, BY REGION, 2022-2032 ($MILLION)
  • TABLE 12. GLOBAL BUTYLSCOPOLAMINE MARKET FOR ACUTE GENITOURINARY SPASM, BY REGION, 2022-2032 ($MILLION)
  • TABLE 13. GLOBAL BUTYLSCOPOLAMINE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 14. GLOBAL BUTYLSCOPOLAMINE MARKET FOR INJECTION, BY REGION, 2022-2032 ($MILLION)
  • TABLE 15. GLOBAL BUTYLSCOPOLAMINE MARKET FOR ORAL, BY REGION, 2022-2032 ($MILLION)
  • TABLE 16. GLOBAL BUTYLSCOPOLAMINE MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 17. NORTH AMERICA BUTYLSCOPOLAMINE, BY REGION, 2022-2032 ($MILLION)
  • TABLE 18. NORTH AMERICA BUTYLSCOPOLAMINE, BY THERAPY TYPE, 2022-2032 ($MILLION)
  • TABLE 19. NORTH AMERICA BUTYLSCOPOLAMINE, BY CONDITION, 2022-2032 ($MILLION)
  • TABLE 20. NORTH AMERICA BUTYLSCOPOLAMINE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 21. U.S. BUTYLSCOPOLAMINE, BY THERAPY TYPE, 2022-2032 ($MILLION)
  • TABLE 22. U.S. BUTYLSCOPOLAMINE, BY CONDITION, 2022-2032 ($MILLION)
  • TABLE 23. U.S. BUTYLSCOPOLAMINE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 24. CANADA BUTYLSCOPOLAMINE, BY THERAPY TYPE, 2022-2032 ($MILLION)
  • TABLE 25. CANADA BUTYLSCOPOLAMINE, BY CONDITION, 2022-2032 ($MILLION)
  • TABLE 26. CANADA BUTYLSCOPOLAMINE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 27. MEXICO BUTYLSCOPOLAMINE, BY THERAPY TYPE, 2022-2032 ($MILLION)
  • TABLE 28. MEXICO BUTYLSCOPOLAMINE, BY CONDITION, 2022-2032 ($MILLION)
  • TABLE 29. MEXICO BUTYLSCOPOLAMINE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 30. EUROPE BUTYLSCOPOLAMINE, BY REGION, 2022-2032 ($MILLION)
  • TABLE 31. EUROPE BUTYLSCOPOLAMINE, BY THERAPY TYPE, 2022-2032 ($MILLION)
  • TABLE 32. EUROPE BUTYLSCOPOLAMINE, BY CONDITION, 2022-2032 ($MILLION)
  • TABLE 33. EUROPE BUTYLSCOPOLAMINE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 34. FRANCE BUTYLSCOPOLAMINE, BY THERAPY TYPE, 2022-2032 ($MILLION)
  • TABLE 35. FRANCE BUTYLSCOPOLAMINE, BY CONDITION, 2022-2032 ($MILLION)
  • TABLE 36. FRANCE BUTYLSCOPOLAMINE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 37. GERMANY BUTYLSCOPOLAMINE, BY THERAPY TYPE, 2022-2032 ($MILLION)
  • TABLE 38. GERMANY BUTYLSCOPOLAMINE, BY CONDITION, 2022-2032 ($MILLION)
  • TABLE 39. GERMANY BUTYLSCOPOLAMINE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 40. ITALY BUTYLSCOPOLAMINE, BY THERAPY TYPE, 2022-2032 ($MILLION)
  • TABLE 41. ITALY BUTYLSCOPOLAMINE, BY CONDITION, 2022-2032 ($MILLION)
  • TABLE 42. ITALY BUTYLSCOPOLAMINE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 43. SPAIN BUTYLSCOPOLAMINE, BY THERAPY TYPE, 2022-2032 ($MILLION)
  • TABLE 44. SPAIN BUTYLSCOPOLAMINE, BY CONDITION, 2022-2032 ($MILLION)
  • TABLE 45. SPAIN BUTYLSCOPOLAMINE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 46. UK BUTYLSCOPOLAMINE, BY THERAPY TYPE, 2022-2032 ($MILLION)
  • TABLE 47. UK BUTYLSCOPOLAMINE, BY CONDITION, 2022-2032 ($MILLION)
  • TABLE 48. UK BUTYLSCOPOLAMINE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 49. RUSSIA BUTYLSCOPOLAMINE, BY THERAPY TYPE, 2022-2032 ($MILLION)
  • TABLE 50. RUSSIA BUTYLSCOPOLAMINE, BY CONDITION, 2022-2032 ($MILLION)
  • TABLE 51. RUSSIA BUTYLSCOPOLAMINE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 52. REST OF EUROPE BUTYLSCOPOLAMINE, BY THERAPY TYPE, 2022-2032 ($MILLION)
  • TABLE 53. REST OF EUROPE BUTYLSCOPOLAMINE, BY CONDITION, 2022-2032 ($MILLION)
  • TABLE 54. REST OF EUROPE BUTYLSCOPOLAMINE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 55. ASIA-PACIFIC BUTYLSCOPOLAMINE, BY REGION, 2022-2032 ($MILLION)
  • TABLE 56. ASIA-PACIFIC BUTYLSCOPOLAMINE, BY THERAPY TYPE, 2022-2032 ($MILLION)
  • TABLE 57. ASIA-PACIFIC BUTYLSCOPOLAMINE, BY CONDITION, 2022-2032 ($MILLION)
  • TABLE 58. ASIA-PACIFIC BUTYLSCOPOLAMINE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 59. CHINA BUTYLSCOPOLAMINE, BY THERAPY TYPE, 2022-2032 ($MILLION)
  • TABLE 60. CHINA BUTYLSCOPOLAMINE, BY CONDITION, 2022-2032 ($MILLION)
  • TABLE 61. CHINA BUTYLSCOPOLAMINE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 62. JAPAN BUTYLSCOPOLAMINE, BY THERAPY TYPE, 2022-2032 ($MILLION)
  • TABLE 63. JAPAN BUTYLSCOPOLAMINE, BY CONDITION, 2022-2032 ($MILLION)
  • TABLE 64. JAPAN BUTYLSCOPOLAMINE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 65. INDIA BUTYLSCOPOLAMINE, BY THERAPY TYPE, 2022-2032 ($MILLION)
  • TABLE 66. INDIA BUTYLSCOPOLAMINE, BY CONDITION, 2022-2032 ($MILLION)
  • TABLE 67. INDIA BUTYLSCOPOLAMINE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 68. SOUTH KOREA BUTYLSCOPOLAMINE, BY THERAPY TYPE, 2022-2032 ($MILLION)
  • TABLE 69. SOUTH KOREA BUTYLSCOPOLAMINE, BY CONDITION, 2022-2032 ($MILLION)
  • TABLE 70. SOUTH KOREA BUTYLSCOPOLAMINE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 71. AUSTRALIA BUTYLSCOPOLAMINE, BY THERAPY TYPE, 2022-2032 ($MILLION)
  • TABLE 72. AUSTRALIA BUTYLSCOPOLAMINE, BY CONDITION, 2022-2032 ($MILLION)
  • TABLE 73. AUSTRALIA BUTYLSCOPOLAMINE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 74. THAILAND BUTYLSCOPOLAMINE, BY THERAPY TYPE, 2022-2032 ($MILLION)
  • TABLE 75. THAILAND BUTYLSCOPOLAMINE, BY CONDITION, 2022-2032 ($MILLION)
  • TABLE 76. THAILAND BUTYLSCOPOLAMINE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 77. MALAYSIA BUTYLSCOPOLAMINE, BY THERAPY TYPE, 2022-2032 ($MILLION)
  • TABLE 78. MALAYSIA BUTYLSCOPOLAMINE, BY CONDITION, 2022-2032 ($MILLION)
  • TABLE 79. MALAYSIA BUTYLSCOPOLAMINE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 80. INDONESIA BUTYLSCOPOLAMINE, BY THERAPY TYPE, 2022-2032 ($MILLION)
  • TABLE 81. INDONESIA BUTYLSCOPOLAMINE, BY CONDITION, 2022-2032 ($MILLION)
  • TABLE 82. INDONESIA BUTYLSCOPOLAMINE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 83. REST OF ASIA PACIFIC BUTYLSCOPOLAMINE, BY THERAPY TYPE, 2022-2032 ($MILLION)
  • TABLE 84. REST OF ASIA PACIFIC BUTYLSCOPOLAMINE, BY CONDITION, 2022-2032 ($MILLION)
  • TABLE 85. REST OF ASIA PACIFIC BUTYLSCOPOLAMINE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 86. LAMEA BUTYLSCOPOLAMINE, BY REGION, 2022-2032 ($MILLION)
  • TABLE 87. LAMEA BUTYLSCOPOLAMINE, BY THERAPY TYPE, 2022-2032 ($MILLION)
  • TABLE 88. LAMEA BUTYLSCOPOLAMINE, BY CONDITION, 2022-2032 ($MILLION)
  • TABLE 89. LAMEA BUTYLSCOPOLAMINE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 90. BRAZIL BUTYLSCOPOLAMINE, BY THERAPY TYPE, 2022-2032 ($MILLION)
  • TABLE 91. BRAZIL BUTYLSCOPOLAMINE, BY CONDITION, 2022-2032 ($MILLION)
  • TABLE 92. BRAZIL BUTYLSCOPOLAMINE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 93. SOUTH AFRICA BUTYLSCOPOLAMINE, BY THERAPY TYPE, 2022-2032 ($MILLION)
  • TABLE 94. SOUTH AFRICA BUTYLSCOPOLAMINE, BY CONDITION, 2022-2032 ($MILLION)
  • TABLE 95. SOUTH AFRICA BUTYLSCOPOLAMINE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 96. SAUDI ARABIA BUTYLSCOPOLAMINE, BY THERAPY TYPE, 2022-2032 ($MILLION)
  • TABLE 97. SAUDI ARABIA BUTYLSCOPOLAMINE, BY CONDITION, 2022-2032 ($MILLION)
  • TABLE 98. SAUDI ARABIA BUTYLSCOPOLAMINE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 99. UAE BUTYLSCOPOLAMINE, BY THERAPY TYPE, 2022-2032 ($MILLION)
  • TABLE 100. UAE BUTYLSCOPOLAMINE, BY CONDITION, 2022-2032 ($MILLION)
  • TABLE 101. UAE BUTYLSCOPOLAMINE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 102. ARGENTINA BUTYLSCOPOLAMINE, BY THERAPY TYPE, 2022-2032 ($MILLION)
  • TABLE 103. ARGENTINA BUTYLSCOPOLAMINE, BY CONDITION, 2022-2032 ($MILLION)
  • TABLE 104. ARGENTINA BUTYLSCOPOLAMINE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 105. REST OF LAMEA BUTYLSCOPOLAMINE, BY THERAPY TYPE, 2022-2032 ($MILLION)
  • TABLE 106. REST OF LAMEA BUTYLSCOPOLAMINE, BY CONDITION, 2022-2032 ($MILLION)
  • TABLE 107. REST OF LAMEA BUTYLSCOPOLAMINE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 108. GUANGDONG ZHONGSHENG PHARMACEUTICAL: KEY EXECUTIVES
  • TABLE 109. GUANGDONG ZHONGSHENG PHARMACEUTICAL: COMPANY SNAPSHOT
  • TABLE 110. GUANGDONG ZHONGSHENG PHARMACEUTICAL: OPERATING SEGMENTS
  • TABLE 111. GUANGDONG ZHONGSHENG PHARMACEUTICAL: PRODUCT PORTFOLIO
  • TABLE 112. GUANGDONG ZHONGSHENG PHARMACEUTICAL: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 113. WANBANGDE PHARMACEUTICAL GROUP: KEY EXECUTIVES
  • TABLE 114. WANBANGDE PHARMACEUTICAL GROUP: COMPANY SNAPSHOT
  • TABLE 115. WANBANGDE PHARMACEUTICAL GROUP: OPERATING SEGMENTS
  • TABLE 116. WANBANGDE PHARMACEUTICAL GROUP: PRODUCT PORTFOLIO
  • TABLE 117. WANBANGDE PHARMACEUTICAL GROUP: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 118. SHANDONG YIJIAN PHARMACEUTICAL SIGMA-ALDRICH: KEY EXECUTIVES
  • TABLE 119. SHANDONG YIJIAN PHARMACEUTICAL SIGMA-ALDRICH: COMPANY SNAPSHOT
  • TABLE 120. SHANDONG YIJIAN PHARMACEUTICAL SIGMA-ALDRICH: OPERATING SEGMENTS
  • TABLE 121. SHANDONG YIJIAN PHARMACEUTICAL SIGMA-ALDRICH: PRODUCT PORTFOLIO
  • TABLE 122. SHANDONG YIJIAN PHARMACEUTICAL SIGMA-ALDRICH: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 123. ALKALOIDA CORP: KEY EXECUTIVES
  • TABLE 124. ALKALOIDA CORP: COMPANY SNAPSHOT
  • TABLE 125. ALKALOIDA CORP: OPERATING SEGMENTS
  • TABLE 126. ALKALOIDA CORP: PRODUCT PORTFOLIO
  • TABLE 127. ALKALOIDA CORP: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 128. SYNTREE: KEY EXECUTIVES
  • TABLE 129. SYNTREE: COMPANY SNAPSHOT
  • TABLE 130. SYNTREE: OPERATING SEGMENTS
  • TABLE 131. SYNTREE: PRODUCT PORTFOLIO
  • TABLE 132. SYNTREE: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 133. LINNEA: KEY EXECUTIVES
  • TABLE 134. LINNEA: COMPANY SNAPSHOT
  • TABLE 135. LINNEA: OPERATING SEGMENTS
  • TABLE 136. LINNEA: PRODUCT PORTFOLIO
  • TABLE 137. LINNEA: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 138. AVACHEM SCIENTIFIC: KEY EXECUTIVES
  • TABLE 139. AVACHEM SCIENTIFIC: COMPANY SNAPSHOT
  • TABLE 140. AVACHEM SCIENTIFIC: OPERATING SEGMENTS
  • TABLE 141. AVACHEM SCIENTIFIC: PRODUCT PORTFOLIO
  • TABLE 142. AVACHEM SCIENTIFIC: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 143. WOLVES RANDD CHEMICAL: KEY EXECUTIVES
  • TABLE 144. WOLVES RANDD CHEMICAL: COMPANY SNAPSHOT
  • TABLE 145. WOLVES RANDD CHEMICAL: OPERATING SEGMENTS
  • TABLE 146. WOLVES RANDD CHEMICAL: PRODUCT PORTFOLIO
  • TABLE 147. WOLVES RANDD CHEMICAL: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 148. BOEHRINGER INGELHEIM: KEY EXECUTIVES
  • TABLE 149. BOEHRINGER INGELHEIM: COMPANY SNAPSHOT
  • TABLE 150. BOEHRINGER INGELHEIM: OPERATING SEGMENTS
  • TABLE 151. BOEHRINGER INGELHEIM: PRODUCT PORTFOLIO
  • TABLE 152. BOEHRINGER INGELHEIM: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 153. SANDOZ (NOVARTIS): KEY EXECUTIVES
  • TABLE 154. SANDOZ (NOVARTIS): COMPANY SNAPSHOT
  • TABLE 155. SANDOZ (NOVARTIS): OPERATING SEGMENTS
  • TABLE 156. SANDOZ (NOVARTIS): PRODUCT PORTFOLIO
  • TABLE 157. SANDOZ (NOVARTIS): KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 158. JIANGSU ANGE PHARMACEUTICAL: KEY EXECUTIVES
  • TABLE 159. JIANGSU ANGE PHARMACEUTICAL: COMPANY SNAPSHOT
  • TABLE 160. JIANGSU ANGE PHARMACEUTICAL: OPERATING SEGMENTS
  • TABLE 161. JIANGSU ANGE PHARMACEUTICAL: PRODUCT PORTFOLIO
  • TABLE 162. JIANGSU ANGE PHARMACEUTICAL: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 163. CHENGDU FIRST PHARMACEUTICAL: KEY EXECUTIVES
  • TABLE 164. CHENGDU FIRST PHARMACEUTICAL: COMPANY SNAPSHOT
  • TABLE 165. CHENGDU FIRST PHARMACEUTICAL: OPERATING SEGMENTS
  • TABLE 166. CHENGDU FIRST PHARMACEUTICAL: PRODUCT PORTFOLIO
  • TABLE 167. CHENGDU FIRST PHARMACEUTICAL: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 168. COMBI-BLOCKS: KEY EXECUTIVES
  • TABLE 169. COMBI-BLOCKS: COMPANY SNAPSHOT
  • TABLE 170. COMBI-BLOCKS: OPERATING SEGMENTS
  • TABLE 171. COMBI-BLOCKS: PRODUCT PORTFOLIO
  • TABLE 172. COMBI-BLOCKS: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 173. OXCHEM CORPORATION: KEY EXECUTIVES
  • TABLE 174. OXCHEM CORPORATION: COMPANY SNAPSHOT
  • TABLE 175. OXCHEM CORPORATION: OPERATING SEGMENTS
  • TABLE 176. OXCHEM CORPORATION: PRODUCT PORTFOLIO
  • TABLE 177. OXCHEM CORPORATION: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 178. PARCHEM: KEY EXECUTIVES
  • TABLE 179. PARCHEM: COMPANY SNAPSHOT
  • TABLE 180. PARCHEM: OPERATING SEGMENTS
  • TABLE 181. PARCHEM: PRODUCT PORTFOLIO
  • TABLE 182. PARCHEM: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 183. XI AN TIANXINGJIAN PHARMCHEM: KEY EXECUTIVES
  • TABLE 184. XI AN TIANXINGJIAN PHARMCHEM: COMPANY SNAPSHOT
  • TABLE 185. XI AN TIANXINGJIAN PHARMCHEM: OPERATING SEGMENTS
  • TABLE 186. XI AN TIANXINGJIAN PHARMCHEM: PRODUCT PORTFOLIO
  • TABLE 187. XI AN TIANXINGJIAN PHARMCHEM: KEY STRATEGIC MOVES AND DEVELOPMENTS

  • LIST OF FIGURES

  • FIGURE 1. GLOBAL BUTYLSCOPOLAMINE MARKET SEGMENTATION
  • FIGURE 2. GLOBAL BUTYLSCOPOLAMINE MARKET
  • FIGURE 3. SEGMENTATION BUTYLSCOPOLAMINE MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN BUTYLSCOPOLAMINE MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALBUTYLSCOPOLAMINE MARKET
  • FIGURE 11. BUTYLSCOPOLAMINE MARKET SEGMENTATION, BY BY THERAPY TYPE
  • FIGURE 12. BUTYLSCOPOLAMINE MARKET FOR ANALGESIA, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 13. BUTYLSCOPOLAMINE MARKET FOR SMOOTH MUSCLE RELAXATION, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 14. BUTYLSCOPOLAMINE MARKET FOR RADIOLOGICAL PROCEDURE, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 15. BUTYLSCOPOLAMINE MARKET SEGMENTATION, BY BY CONDITION
  • FIGURE 16. BUTYLSCOPOLAMINE MARKET FOR GASTROINTESTINAL SPASTIC, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 17. BUTYLSCOPOLAMINE MARKET FOR ACUTE BILIARY SPASM, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 18. BUTYLSCOPOLAMINE MARKET FOR HYPERMOTILITY DISORDER, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 19. BUTYLSCOPOLAMINE MARKET FOR MENSTRUAL DISTRESS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 20. BUTYLSCOPOLAMINE MARKET FOR PRIMARY DYSMENORRHEA, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 21. BUTYLSCOPOLAMINE MARKET FOR MUSCLE SPASM, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 22. BUTYLSCOPOLAMINE MARKET FOR ACUTE GENITOURINARY SPASM, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 23. BUTYLSCOPOLAMINE MARKET SEGMENTATION, BY BY APPLICATION
  • FIGURE 24. BUTYLSCOPOLAMINE MARKET FOR INJECTION, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 25. BUTYLSCOPOLAMINE MARKET FOR ORAL, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 26. TOP WINNING STRATEGIES, BY YEAR, 2020-2022*
  • FIGURE 27. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2020-2022*
  • FIGURE 28. TOP WINNING STRATEGIES, BY COMPANY, 2020-2022*
  • FIGURE 29. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 30. COMPETITIVE DASHBOARD
  • FIGURE 31. COMPETITIVE HEATMAP: BUTYLSCOPOLAMINE MARKET
  • FIGURE 32. Top player positioning, 2022
  • FIGURE 33. GUANGDONG ZHONGSHENG PHARMACEUTICAL: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 34. GUANGDONG ZHONGSHENG PHARMACEUTICAL: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 35. GUANGDONG ZHONGSHENG PHARMACEUTICAL: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 36. WANBANGDE PHARMACEUTICAL GROUP: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 37. WANBANGDE PHARMACEUTICAL GROUP: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 38. WANBANGDE PHARMACEUTICAL GROUP: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 39. SHANDONG YIJIAN PHARMACEUTICAL SIGMA-ALDRICH: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 40. SHANDONG YIJIAN PHARMACEUTICAL SIGMA-ALDRICH: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 41. SHANDONG YIJIAN PHARMACEUTICAL SIGMA-ALDRICH: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 42. ALKALOIDA CORP: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 43. ALKALOIDA CORP: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 44. ALKALOIDA CORP: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 45. SYNTREE: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 46. SYNTREE: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 47. SYNTREE: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 48. LINNEA: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 49. LINNEA: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 50. LINNEA: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 51. AVACHEM SCIENTIFIC: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 52. AVACHEM SCIENTIFIC: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 53. AVACHEM SCIENTIFIC: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 54. WOLVES RANDD CHEMICAL: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 55. WOLVES RANDD CHEMICAL: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 56. WOLVES RANDD CHEMICAL: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 57. BOEHRINGER INGELHEIM: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 58. BOEHRINGER INGELHEIM: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 59. BOEHRINGER INGELHEIM: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 60. SANDOZ (NOVARTIS): NET SALES, 2020-2022 ($MILLION)
  • FIGURE 61. SANDOZ (NOVARTIS): REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 62. SANDOZ (NOVARTIS): REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 63. JIANGSU ANGE PHARMACEUTICAL: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 64. JIANGSU ANGE PHARMACEUTICAL: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 65. JIANGSU ANGE PHARMACEUTICAL: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 66. CHENGDU FIRST PHARMACEUTICAL: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 67. CHENGDU FIRST PHARMACEUTICAL: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 68. CHENGDU FIRST PHARMACEUTICAL: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 69. COMBI-BLOCKS: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 70. COMBI-BLOCKS: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 71. COMBI-BLOCKS: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 72. OXCHEM CORPORATION: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 73. OXCHEM CORPORATION: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 74. OXCHEM CORPORATION: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 75. PARCHEM: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 76. PARCHEM: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 77. PARCHEM: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 78. XI AN TIANXINGJIAN PHARMCHEM: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 79. XI AN TIANXINGJIAN PHARMCHEM: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 80. XI AN TIANXINGJIAN PHARMCHEM: REVENUE SHARE, BY REGION, 2032 (%)

 
 
With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

  • Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
  • Technologically sophisticated and reliable insights through well audited and veracious research methodology
  • Sovereign research proceeds that present a tangible depiction of marketplace


With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, web-casts and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast


Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develops analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth and forecasts


Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

  • Chief executives and VPs of leading corporations specific to industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)


Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.

PURCHASE OPTIONS

Call or Email us

U.S.-Canada Toll-free: +1-800-792-5285
Int'l : +1-503-894-6022
Europe : +44-845-528-1300
Email : help@alliedmarketresearch.com

Looking for Customization?

 Customization Request

Have a Question?

 Speak with Analyst

Any Confusion?

 Inquire Before Buying

Have a glance of the Report

  Enquiry Now
RELATED TAGS

Purchase Full Report of
Butylscopolamine Market

Start reading.
This Report and over 68,113+ more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,690
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  • Free industry update
    (Within 180 days)
  • Free report update in next update cycle
  • Data Pack
  • $3,930
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Single User
  • $5,820
  • Restricted to one authorized user
  • One print only
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Five Users
  • $6,540
  • Limited to five authorized users
  • Print upto five copies
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle

  • Enterprise
    License/PDF

  • $9,870
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle

  • Library
    Membership

  • $999 $ 1,175
    Per User/ Per month/ Billed annually
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

RELATED REPORTS
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

Get Industry Data Alerts

Why Allied Market Research?

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers